21103 ⎘
Medicinal preparations containing antigens or antibodies; Bacterial antigens; Pseudomonas Pseudomonadales, e.g. Moraxella
IMMUNOGENIC COMPOSITIONS AND METHODS FOR REDUCING TRANSMISSION OF PATHOGENS
#2DEVELOPMENT OF SYNTHETIC PSEUDAMINIC ACID-BASED ANTIBACTERIAL VACCINES AGAINST ACINETOBACTER BAUMANNII
#3IMMUNOGENIC COMPOSITION, USE AND METHODS
#4Hyper-Blebbing Bacteria
#5COMPOSITIONS AND METHODS FOR A MULTI-ADJUVANT ONLY APPROACH TO IMMUNOPROPHYLAXIS FOR PREVENTING INFECTIONS
#6PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE
#7IMMUNOGENIC COMPOSITION
#8Vaccine delivery method
#9PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE
#10Vaccines targeting M. catharrhalis
#11IMMUNOGENIC COMPOSITION, USE AND METHOD OF TREATMENT
#12immunogenic protein and composition and application thereof
#13Vaccine delivery method
#14Immunogenic Composition
#15Compositions and methods for a multi-adjuvant only approach to immunoprophylaxis for preventing infections
#16UspA2 protein constructs and uses thereof
#17Live attenuated vaccines
#18Methods of boosting immune responses
#19Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers
#20Immunogenic composition, use and method of treatment
#21Targets of
#22VACCINE AGAINST MORAXELLA CATARRHALIS
#23Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
#24Immunogenic Compositions and Vaccines Derived From Bacterial Surface Receptor Proteins
#25Targets of
#26UspA2 protein constructs and uses thereof
#27Targets of acinetobacter baumannii
#28Targets of acinetobacter baumannii
#29Targets of
#30Targets of
#31Targets of
#32Targets of
#33Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers
#34Targets of acinetobacter baumannii
#35Interaction of moraxella catarrhalis with epithellal cells, extracellular matrix proteins and the complement system
#36VACCINE DELIVERY METHOD
#37Vaccine compositions comprising a saponin adjuvant
#38Immunostimulatory anti-CEACAM1 antibody
#39UspA2 protein constructs and uses thereof
#40SYNTHETIC OLIGOSACCHARIDES FOR MORAXELLA VACCINE
#41Compositions and Methods for Treatment of Bacterial Infections
#42Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
#43Immunogenic compositions and vaccines derived from bacterial surface receptor proteins
#44Tissue targeted antigenic activation of the immune response to treat cancers
#45Live attenuated vaccines
#46Tissue targeted antigenic activation of the immune response to treat cancers
#47Interaction of with epithelial cells, extracellular matrix proteins and the complement system
#48Targets of
#49Interaction of with epithelial cells, extracellular matrix proteins and the complement system
#50Immunogenic anti-inflammatory compositions
#51Interaction of with epithelial cells, extracellular matrix proteins and the complement system
#52NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS
#53NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS
#54NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS
#55LPS Based Vaccines
#56Vaccine compositions comprising a saponin adjuvant
#57Tissue targeted antigenic activation of the immune response to treat cancers
#58Identification of a conserved inner core oligosaccharide of lipopolysaccharide as a vaccine antigen
#59Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis
#60METHOD FOR REFOLDING NEISSERIAL NSPA PROTEIN
#61Interaction of with epithelial cells, extracellular matrix proteins and the complement system
#62NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA
#63Method for stimulating immune response against
#64Vaccine Compositions Comprising a Saponin Adjuvant
#65Method for Refolding Neisserial Nspa Protein
#66Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
#67Non-toxic mutants of pathogenic gram-negative bacteria
#68TISSUE TARGETED ANTIGENIC ACTIVATION OF THE IMMUNE RESPONSE TO CANCERS
#69Non-toxic mutants of pathogenic gram-negative bacteria
#70Neisserial vaccine compositions comprising a combination of antigens
#71Cross-protective epitopes of moraxella catarrhalis and use thereof
#72Mutant protein and refolding method
#73Intranasal immunization with detoxified lipooligosaccharide from nontypeable or
#74Vaccine composition
#75Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-
#76Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
#77Polypeptides of ()
#78Non-toxic mutants of pathogenic gram-negative bacteria